↗6 Form 4 rows in the window
Covers original filings from Aug 1, 2026 to Oct 29, 2026. Older trades and amendments are in the SEC history.
$0.00Bought on the market
$5.3MSold on the market
1Companies
Oct 2, 2026Latest filing
| Company | Title | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202621:29 | Oct 1, 2026from Sep 30, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $90.47 | −25,000 | 79,762 | -24% | −$2.3M | ||
| Oct 2, 202621:29 | Oct 1, 2026from Sep 30, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +25,000 | 87,262 | +40% | $363K | ||
| Sep 3, 202621:33 | Sep 2, 2026from Sep 1, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $88.75 | −25,732 | 79,762 | -24% | −$2.3M | ||
| Sep 3, 202621:33 | Sep 1, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +7,500 | 105,494 | +8% | $109K | ||
| Aug 5, 202621:32 | Aug 3, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | S · Sell10b5-1 | $95.57 | −7,500 | 97,994 | -7% | −$717K | ||
| Aug 5, 202621:32 | Aug 3, 2026 | SYRESpyre Therapeutics, Inc. | Chief Financial Officer | M · Exercise10b5-1 | $14.50 | +7,500 | 105,494 | +8% | $109K |